Solid Biosciences (SLDB) Current Assets (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Current Assets data on file, last reported at $396.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 26.6% year-over-year to $396.8 million; the trailing twelve-month figure through Mar 2026 stood at $396.8 million (up 26.6% YoY), and the FY2025 full-year result was $205.5 million, up 30.61% from the prior year.
• Current Assets climbed to $396.8 million in Q1 2026, from $205.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $396.8 million in Q1 2026 to a low of $129.7 million in Q4 2023.
• A 5-year average of $209.4 million and a median of $197.6 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets tumbled 40.93% in 2023 and surged 46.32% in 2025, its largest moves.
• Tracing SLDB's Current Assets over 5 years: stood at $219.6 million in 2022, then plunged by 40.93% to $129.7 million in 2023, then gained by 21.25% to $157.3 million in 2024, then soared by 30.61% to $205.5 million in 2025, then soared by 93.13% to $396.8 million in 2026.
• Business Quant data shows SLDB's Current Assets at $396.8 million in Q1 2026, $205.5 million in Q4 2025, and $244.9 million in Q3 2025.